CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in April. Cantor Virtual Muscular Dystrophy Symposium Date:... Read More

INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-six-month or annual subcutaneous dosing; clinical trial initiation expected 1Q 2025 Dose escalation ongoing in RestorAATion-1 clinical trial of WVE-006, industry’s first-ever RNA editing candidate in the clinic; GalNAc... Read More

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 6, 2024, to review the company’s fourth quarter and full year 2023 financial results and provide business updates. The webcast and... Read More

Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which are important for potential muscle regeneration Presentations also include non-human primate data demonstrating significant concentrations of WVE-N531 in heart, diaphragm and skeletal muscle, as well as preclinical data for potential future DMD programs targeting other exons... Read More

Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans Selection of clinical candidate for GalNAc-siRNA INHBE program in obesity now planned for 3Q 2024, ahead of prior expectation; designed to reduce fat, spare muscle mass, and restore and maintain a healthy metabolic profile Dosing underway in... Read More

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10,... Read More

FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024 Previous clinical proof-of-concept data demonstrated highest level of exon skipping ever observed in the clinic and that WVE-N531 was present in myogenic stem cells, which are important for potential muscle regeneration CAMBRIDGE, Mass., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a... Read More

CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public offering of 20,000,000 of its ordinary shares at a price to the public of $5.00 per ordinary share. Gross proceeds to Wave Life... Read More

CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has commenced an underwritten public offering of $100 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded... Read More

WVE-006 is uniquely designed to correct the disease-causing RNA mutation in AATD, thereby restoring circulation of wild-type M-AAT protein and reducing Z-AAT protein levels to address both lung and liver manifestations of the disease Wave earned $20 million USD milestone from GSK for initiation of dosing; eligible for additional development, launch, and sales-related milestones of up to $505 million for WVE-006... Read More

CAMBRIDGE, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 6 th Annual Evercore ISI HealthCONx Conference in Miami, FL... Read More

Initiated RestorAATion clinical program for WVE-006, industry’s first-ever RNA editing clinical candidate, following approval of CTAs; dosing on track for 4Q 2023 and first-in-human proof-of-mechanism data anticipated in 2024 On track to deliver dystrophin data from potentially registrational FORWARD-53 trial of WVE-N531 in 2024 Enrollment complete in 30 mg multi-dose cohort of SELECT-HD with clinical data for... Read More

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, November 9, 2023, to review the company’s third quarter 2023 financial results and provide business updates. The webcast and... Read More

Presented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disorders, including obesity, which uses Wave’s best-in-class GalNAc-siRNA capabilities and novel genetic insights from GSK WVE-006 – industry’s first-ever RNA editing clinical candidate – on track for dosing in RestorAATion clinical trial in 4Q 2023 and first human proof-of-mechanism data in 2024 Advancing multiple,... Read More

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the Chardan 7 th Annual Genetic Medicines Conference in New York City on Monday, October 2, 2023.... Read More

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a virtual analyst-led fireside chat at the H.C. Wainwright 25 th Annual Global Investment... Read More

WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (AAT) protein and reduce levels of mutant Z-AAT protein, thereby addressing alpha-1 antitrypsin deficiency-related lung disease, liver disease or both Wave expects to initiate dosing in the first-in-human clinical program in 4Q 2023 and deliver AAT... Read More

Preparing for imminent submission of clinical trial applications (CTAs) for GalNAc-conjugated AATD candidate (WVE-006), the industry’s first RNA editing clinical candidate Novel DMD therapeutic candidate (WVE-N531) with best-in-class exon skipping clinical data is on track to enter a potentially registrational Phase 2 clinical study in 2H 2023, with dystrophin data expected in 2024 “R&D Day” virtual event planned for... Read More

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 3, 2023, to review the company’s second quarter 2023 financial results and provide business updates. The webcast and... Read More

CAMBRIDGE, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that the company has been added to the small-cap Russell 2000® and broad-market all-cap Russell 3000® Indexes as part of the annual reconstitution, effective after the U.S. market opens... Read More

Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not show clinical benefit compared with placebo; additionally, poly(GP) reductions did not correlate with clinical outcomes -- Wave to discontinue development of WVE-004 Wave to host investor conference call at 8:30 a.m. ET today CAMBRIDGE, Mass.,... Read More

Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD) which is designed to restore healthy, wild-type AAT protein Best-in-class exon skipping clinical data for WVE-N531 in Duchenne muscular dystrophy (DMD) also highlighted in oral presentation Poster presentations will focus on Wave’s pioneering... Read More

Emerging leader in RNA medicines with multi-modal discovery and development platform and first-in-class RNA editing programs Rapidly advancing toward 2023 CTA submissions and first-in-human study for WVE-006, the industry’s first RNA editing clinical candidate Planning for potentially registrational Phase 2 clinical study for WVE-N531 to assess functional dystrophin protein restoration in DMD patients, following... Read More

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, May 3, 2023, to review the company’s first quarter 2023 financial results and provide business updates. The webcast and... Read More

Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability in vivo versus comparator siRNA formats RNAi is one of multiple Wave modalities being advanced in strategic research collaboration with GSK CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic... Read More

CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Guggenheim Genomic Medicines and Rare Disease Days in... Read More

Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic Extended leadership in RNA editing and advanced WVE-006 for AATD – first-in-class RNA editing candidate transitioning to clinical development in 2023 Initiating Part B of WVE-N531 study in exon 53-amenable DMD to assess dystrophin after 24 and 48 weeks of... Read More

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 22, 2023, to discuss the company’s fourth quarter and full year 2022 financial results... Read More

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the SVB Securities Global Biopharma Conference at 10:00 a.m. ET on... Read More

53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing PN chemistry improved pharmacology of WVE-N531 compared with Wave’s first-generation DMD program – demonstrated high muscle concentrations with a mean of 42 micrograms/gram WVE-N531 appeared safe and well tolerated Third Wave clinical trial evaluating a PN chemistry-containing compound to achieve target engagement... Read More

Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties Collaboration brings together Wave’s PRISM™ oligonucleotide platform and GSK’s expertise in genetics and genomics GSK to advance up to eight preclinical programs Additionally, GSK receives exclusive global license to Wave’s preclinical, potential first-in-class RNA editing program, WVE-006, to treat... Read More